CA2370884A1 - Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer - Google Patents
Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer Download PDFInfo
- Publication number
- CA2370884A1 CA2370884A1 CA002370884A CA2370884A CA2370884A1 CA 2370884 A1 CA2370884 A1 CA 2370884A1 CA 002370884 A CA002370884 A CA 002370884A CA 2370884 A CA2370884 A CA 2370884A CA 2370884 A1 CA2370884 A1 CA 2370884A1
- Authority
- CA
- Canada
- Prior art keywords
- mitochondrial
- disease
- single nucleotide
- alzheimer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 209
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 204
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 79
- 102000054765 polymorphisms of proteins Human genes 0.000 title claims abstract description 49
- 108020005196 Mitochondrial DNA Proteins 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 230000002438 mitochondrial effect Effects 0.000 claims description 74
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 239000000523 sample Substances 0.000 claims description 53
- 239000012472 biological sample Substances 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 108020004566 Transfer RNA Proteins 0.000 claims description 38
- 238000009396 hybridization Methods 0.000 claims description 37
- 108090000365 Cytochrome-c oxidases Proteins 0.000 claims description 30
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 23
- 108700026220 vif Genes Proteins 0.000 claims description 21
- 102000006746 NADH Dehydrogenase Human genes 0.000 claims description 20
- 108010086428 NADH Dehydrogenase Proteins 0.000 claims description 20
- 108010075028 Cytochromes b Proteins 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 15
- 238000003499 nucleic acid array Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 10
- 108700022487 rRNA Genes Proteins 0.000 claims description 10
- 230000007170 pathology Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000004898 mitochondrial function Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 abstract description 63
- 239000000203 mixture Substances 0.000 abstract description 12
- 210000003470 mitochondria Anatomy 0.000 description 133
- 210000004027 cell Anatomy 0.000 description 84
- 108020004414 DNA Proteins 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 54
- 239000013615 primer Substances 0.000 description 53
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 40
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 17
- 108091006112 ATPases Proteins 0.000 description 15
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- 108700036248 MT-RNR1 Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108091060210 Heavy strand Proteins 0.000 description 8
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 108091092356 cellular DNA Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 101710095339 Apolipoprotein E Proteins 0.000 description 7
- 102100029470 Apolipoprotein E Human genes 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 7
- 206010029260 Neuroblastoma Diseases 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000007984 Tris EDTA buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000027721 electron transport chain Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101150001086 COB gene Proteins 0.000 description 4
- 102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 4
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 4
- 101150053771 MT-CYB gene Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 101150006264 ctb-1 gene Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000005153 frontal cortex Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 101150088166 mt:Cyt-b gene Proteins 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- FPGSEBKFEJEOSA-UMMCILCDSA-N 8-Hydroxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O FPGSEBKFEJEOSA-UMMCILCDSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102100025287 Cytochrome b Human genes 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
- 101001109060 Homo sapiens NADH-ubiquinone oxidoreductase chain 4L Proteins 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 201000009035 MERRF syndrome Diseases 0.000 description 2
- 102100021452 NADH-ubiquinone oxidoreductase chain 4L Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- -1 catabolites Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000030251 communication disease Diseases 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 102220203911 rs1057522817 Human genes 0.000 description 2
- 102220057367 rs730881426 Human genes 0.000 description 2
- 102220200497 rs753441393 Human genes 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- OCFBEACKJONPRZ-YEOHUATISA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione;2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound O=C1CC(=O)NC(=S)N1.C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OCFBEACKJONPRZ-YEOHUATISA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZCYDQSUQFINRLP-UHFFFAOYSA-N AD-I Natural products CC=C(C)/C(=O)OC1C(OC(=O)CC(C)C)c2cc3C=CC(=O)Oc3cc2OC1(C)C ZCYDQSUQFINRLP-UHFFFAOYSA-N 0.000 description 1
- 241000585703 Adelphia <angiosperm> Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101150018198 COX1 gene Proteins 0.000 description 1
- 101150043980 COXI gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101710081048 Endonuclease III Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 101150079116 MT-CO1 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 101710187199 Thermostable alkaline protease Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ZYPGADGCNXOUJP-CXVPHVKISA-N Variotin Chemical compound CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O ZYPGADGCNXOUJP-CXVPHVKISA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 102220370380 c.1809T>C Human genes 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 101150087530 mt:ATPase6 gene Proteins 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 102200062276 rs397514808 Human genes 0.000 description 1
- 102200062300 rs397514880 Human genes 0.000 description 1
- 102220037138 rs587780244 Human genes 0.000 description 1
- 102220058246 rs730881626 Human genes 0.000 description 1
- 102220276290 rs782343800 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur des compositions et des méthodes fondées sur la détermination de polymorphismes de nucléotides simples dans l'ADN mt ou dans des mutations homoplasmiques d'ADN mt, utilisées pour détecter la présence de la maladie d'Alzheimer (AD) ou le risque de l'avoir, et pour identifier des agents appropriés pour traiter cette maladie.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13044799P | 1999-04-20 | 1999-04-20 | |
| US60/130,447 | 1999-04-20 | ||
| US16090199P | 1999-10-22 | 1999-10-22 | |
| US60/160,901 | 1999-10-22 | ||
| PCT/US2000/010906 WO2000063441A2 (fr) | 1999-04-20 | 2000-04-19 | Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2370884A1 true CA2370884A1 (fr) | 2000-10-26 |
Family
ID=26828492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002370884A Abandoned CA2370884A1 (fr) | 1999-04-20 | 2000-04-19 | Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1208225A2 (fr) |
| JP (1) | JP2003521879A (fr) |
| AU (1) | AU4368300A (fr) |
| CA (1) | CA2370884A1 (fr) |
| WO (1) | WO2000063441A2 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040034582A (ko) * | 2000-12-04 | 2004-04-28 | 프리마겐 홀딩 비.브이. | 내공생체 세포소기관의 시험 및 그것에 의해 동정할 수있는 화합물 |
| WO2005056573A1 (fr) * | 2002-06-10 | 2005-06-23 | 1304854 Ontario Ltd. | Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante |
| GB2380194B (en) * | 2001-10-01 | 2005-06-22 | Roger Michael Marchbanks | A mitochondrial mutation associated with schizophrenia and increased oxidative stress |
| US6897025B2 (en) * | 2002-01-07 | 2005-05-24 | Perlegen Sciences, Inc. | Genetic analysis systems and methods |
| CA2513191A1 (fr) * | 2003-01-30 | 2004-08-12 | Research Development Foundation | Procedes et compositions d'analyse de l'expression genique liee a la mitochondrie |
| BRPI0410789B8 (pt) | 2003-05-21 | 2021-05-25 | Andes Biotechnologies Global Inc | composição farmacêutica, uso de um ou mais oligonucleotídeos, e, método de detecção |
| KR101363032B1 (ko) | 2005-04-18 | 2014-02-13 | 미토믹스 인크. | 일광 노출, 전립선암 및 다른 암의 검출용 진단 도구로서미토콘드리아 돌연변이 및 전위 |
| US20130022979A1 (en) | 2005-04-18 | 2013-01-24 | Genesis Genomics Inc. | 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER |
| EP2557421A3 (fr) * | 2007-03-23 | 2013-06-05 | King's College London | Activité mitochondriale altérée dans les maladies liées au stress oxydant |
| EP2593787B1 (fr) * | 2010-07-16 | 2018-07-04 | Stichting VUmc | Méthode d'analyser une prise de sang d'un sujet pour la présence d'un marqueur de la maladie |
| JP5934726B2 (ja) * | 2011-03-18 | 2016-06-15 | フェレニヒング フォール クリステリック ホーヘル オンデルウィス，ウェテンシャペリク オンデルツォーケン パティエンテンツォルフ | 疾患マーカーの存在を被験者の血液サンプルで分析する方法 |
| ES2482866B1 (es) * | 2012-11-22 | 2015-05-12 | Consejo Superior De Investigaciones Científicas (Csic) | Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas. |
| ES2546743B1 (es) * | 2014-03-28 | 2016-07-07 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Marcadores mitocondriales de enfermedades neurodegenerativas |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| TW202033760A (zh) * | 2018-11-28 | 2020-09-16 | 國立大學法人千葉大學 | 多因素遺傳疾病的基因檢測法、及檢測套件 |
| CN113862346B (zh) * | 2021-09-26 | 2023-07-07 | 北京大学 | 长链非编码rna在治疗阿尔茨海默病中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494794A (en) * | 1992-10-20 | 1996-02-27 | Emory University | Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease |
| US5976798A (en) * | 1994-03-30 | 1999-11-02 | Mitokor | Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid |
| US5565323A (en) * | 1994-03-30 | 1996-10-15 | Mitokor | Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease |
| US6027883A (en) * | 1994-03-30 | 2000-02-22 | Mitokor | Optimal procedure for isolation of mutant mitochondrial alleles |
| JPH1099085A (ja) * | 1996-05-16 | 1998-04-21 | Affymetrix Inc | ヒトミトコンドリアｄｎａの多形性 |
-
2000
- 2000-04-19 CA CA002370884A patent/CA2370884A1/fr not_active Abandoned
- 2000-04-19 AU AU43683/00A patent/AU4368300A/en not_active Abandoned
- 2000-04-19 EP EP00923583A patent/EP1208225A2/fr not_active Withdrawn
- 2000-04-19 JP JP2000612518A patent/JP2003521879A/ja not_active Ceased
- 2000-04-19 WO PCT/US2000/010906 patent/WO2000063441A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000063441A3 (fr) | 2002-03-14 |
| AU4368300A (en) | 2000-11-02 |
| EP1208225A2 (fr) | 2002-05-29 |
| JP2003521879A (ja) | 2003-07-22 |
| WO2000063441A2 (fr) | 2000-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamada et al. | Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression | |
| CA2370884A1 (fr) | Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer | |
| Valiente-Palleja et al. | Comprehensive summary of mitochondrial DNA alterations in the postmortem human brain: A systematic review | |
| HK1214631A1 (zh) | 用於治疗、诊断和监测阿尔茨海默病的方法 | |
| US20100273153A1 (en) | Genetic diagnosis of depression | |
| Sáiz et al. | Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia | |
| WO2003046225A1 (fr) | Polymorphismes d'adn mitochondrial | |
| EP1086249B1 (fr) | Methode diagnostique basee sur la quantification d'adn extramitochondrial | |
| Vawter et al. | Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia | |
| WO2000058519A2 (fr) | Caracterisation de polymorphismes d'un seul nucleotide, dans des regions de codage de genes humains | |
| EP1456418A2 (fr) | Identification de sites polymorphes dans le gene humain mglur8 et utilisations associees | |
| Engert et al. | Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population | |
| Glaser et al. | Linkage disequilibrium mapping of bipolar affective disorder at 12q23‐q24 provides evidence for association at CUX2 and FLJ32356 | |
| US20110038944A1 (en) | Compositions and methods for diagnosis and treatment of hepatobiliary disease and associated disorders | |
| Marlowe et al. | Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk | |
| US20020155446A1 (en) | Very low density lipoprotein receptor polymorphisms and uses therefor | |
| US20110035818A1 (en) | Diagnostic marker and platform for drug design in myocardial infarction and heart failure | |
| US20110269125A1 (en) | Methods and compositions for predicting development of atopic diseases | |
| WO2012167281A2 (fr) | Application clinique mettant en oeuvre de données génétiques pour une gestion efficace de médication | |
| JP5002746B2 (ja) | 抗うつ薬に対する反応性予測に有用な遺伝子多型 | |
| CA2294572A1 (fr) | Compositions genetiques et methodes connexes | |
| Nishio et al. | Hybrid survival motor neuron genes in Japanese patients with spinal muscular atrophy | |
| JP5422805B2 (ja) | 新規糖尿病性腎症感受性遺伝子 | |
| JP2006254735A (ja) | 糖尿病疾患感受性遺伝子、及び糖尿病罹患の難易を検出する方法 | |
| JP4845486B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |